Artigas A, Bernard G R, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, Lamy M, Marini J J, Matthay M A, Pinsky M R, Spragg R, Suter P M
Intensive Care Med. 1998 Apr;24(4):378-98. doi: 10.1007/s001340050585.
The acute respiratory distress syndrome (ARDS) continues as a contributor to the morbidity and mortality of patients in intensive care units throughout the world, imparting tremendous human and financial costs. During the last ten years there has been a decline in ARDS mortality without a clear explanation. The American-European Consensus Committee on ARDS was formed to re-evaluate the standards for the ICU care of patients with acute lung injury (ALI), with regard to ventilatory strategies, the more promising pharmacologic agents, and the definition and quantification of pathological features of ALI that require resolution. It was felt that the definition of strategies for the clinical design and coordination of studies between centers and continents was becoming increasingly important to facilitate the study of various new therapies for ARDS.
急性呼吸窘迫综合征（ARDS）仍是全球重症监护病房患者发病和死亡的一个因素，造成了巨大的人力和财力损失。在过去十年中，ARDS死亡率有所下降，但原因尚不明确。成立了美欧ARDS共识委员会，以重新评估急性肺损伤（ALI）患者重症监护的标准，包括通气策略、更有前景的药物以及需要解决的ALI病理特征的定义和量化。人们认为，制定临床研究设计和各中心及各大洲之间研究协调策略的定义，对于促进ARDS各种新疗法的研究变得越来越重要。
